Press

Mindset Pharma to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5, 2023

Apr 3 • 2 min read

Mindset Pharma Inc. (CSE: MSET / FSE: 9DF / OTCQB: MSSTF), a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today announced that it will participate in the Sequire Cannabis & Psychedelics Conference to be held virtually on Wednesday, April 5, 2023. James Lanthier,…

Filament Health Reports Q4 and Year End 2022 Financial Results and Operational Highlights

Apr 3 • 3 min read

Filament Health Corp. (OTCQB: FLHLF / NEO: FH / FSE: 7QS), a clinical-stage natural psychedelic drug development company, released its fourth quarter financial results and operational highlights for the period ended December 31, 2022. “During the fourth quarter, Filament expanded its revenue-generating partnership network, and announced a worldwide licensing agreement within the treatment of palliative care while…

Apex Labs Meets Endpoints in First-of-its-Kind Take Home Microdose Psilocybin Clinical Trial

Apr 3 • 2 min read

Apex Labs Ltd., a pharmaceutical company optimizing the standard of mental health care with clinically proven psilocybin treatments, is pleased to announce the completion of the first-ever take home microdose psilocybin clinical trial, meeting all endpoints over a two month period with no adverse events. STEP-52 (risk mitigation study evaluating take home synthetic psilocybin) was…

Numinus to Host Q2 2023 Results Conference Call on April 13, 2023

Mar 31 • 2 min read

Numinus Wellness Inc. (TSX: NUMI / OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, will release its financial results for the quarter ended February 28, 2023, after market close on Thursday, April 13, 2023. Interested parties are invited to participate in the Company’s Q2 2023 results conference call and webcast occurring…

Apex Labs Meets Endpoints in First-of-its-Kind Take Home Microdose Psilocybin Clinical Trial

Mar 31 • 2 min read

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435